| Description |
RXPA 380 is a C-terminal specific angiotensin-converting enzyme (ACE) inhibitor with a Ki of 3 nM. RXPA 380 inhibits C-domain mutants of human recombinant ACE with an IC50 of 2.5 nM[1].
|
| Related Catalog |
|
| Target |
Ki: 3 nM (C-terminal ACE), 10 μM (N-terminal ACE)[1] IC50: 2.5 nM (C-domain mutants of human recombinant ACE), 10 μM (N-domain mutants of human recombinant ACE)[1]
|
| In Vitro |
RXPA 380 shows Ki(app) values of 12 nM and 12 μM for the C- and N-domain of mouse somatic ACE[1].
|
| In Vivo |
RXPA 380 (0.9-30 mg/kg; i.v.; once) inhibits ACE activity in mice[1]. Animal Model: Male C57BL6/J mice[1] Dosage: 0.9, 3, 10, and 30 mg/kg Administration: Intravenous infuse for 30 minutes Result: Induced a dose-dependent decrease of the Ang II/Ang I ratio. Blocked the cleavage of exogenously administered bradykinin.
|
